Researchers at ProGenis Pharmaceuticals, in collaboration with Syngenis Labs, are pioneering a new class of RNA-based therapies aimed at addressing insulin resistance, a key driver of type 2 diabetes. Unlike existing GLP-1 receptor agonists, which primarily manage symptoms, these therapies target the disease’s molecular underpinnings by modifying RNA to improve insulin signaling. Syngenis Labs is establishing Australia’s first commercial GMP facility for synthetic RNA, which will facilitate domestic production and reduce reliance on overseas labs, potentially transforming the landscape of diabetes treatment in Australia as global diabetes rates rise.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.smh.com.au/business/companies/wa-biotech-duo-takes-aim-at-diabetes-beyond-ozempic-20260507-p5zupr.html
